Agency: Cordis | Branch: FP7 | Program: CSA-CA | Phase: HEALTH.2010.2.4.4-2 | Award Amount: 2.92M | Year: 2010
Rare diseases represent an important public-health issue, affecting 26-30 million persons across Europe, and a major challenge for research. The fragmentation of resources and knowledge for the 6000-8000 rare diseases and the lack of treatment for the majority of them necessitate a coordinated European approach to unravel the underlying molecular defects and pathophysiological mechanisms. The low number of affected patients requires transnational collaboration with multidisciplinary approaches to map prevalences, build patient registries, identify biomarkers, develop new diagnostics and finally perform clinical studies for the development of treatments. The successful linking of research funding organisations in E-Rare-1 and the subsequent exemplary joint funding activities have attested the need of, and the acknowledgment from, the research community for transnational funding of collaborative, multidisciplinary and ambitious projects on rare diseases. It has leveraged funding for rare disease research in countries without specific programmes for rare diseases and thus enabled the participation of researchers in these countries to transnational projects. The E-Rare-2 project aims at deepening and extending the cooperation among the E-Rare-1 and the five new partners by systematic exchange of information, yearly launching of joint calls, thorough assessment of the funding mechanisms and results of the funded research projects and, finally, strategic activities aiming at a sustainable development and extension of the network. Special attention will be given to the outreach and knowledge exchange with new member states, countries outside of Europe and key stakeholders/initiatives important for rare diseases. E-Rare-2 activities will thus further contribute to reducing fragmentation of research and resources through the enhanced coordination and transnational funding of excellent research on rare diseases, thereby shaping the European Research Area for rare diseases.
I-MOVE-plus - I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-17-2014 | Award Amount: 7.52M | Year: 2015
The I-MOVE\ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the effectiveness (VE) and impact (VI) of influenza and Pneumococcal vaccines and vaccination strategies a in the elderly population in Europe. The goal is to develop a sustainable platform of primary care practices, hospitals and laboratory networks that share validated methods to evaluate post marketing vaccine performances. The objectives are to identify, pilot test, and disseminate in EU the best study designs to measure, on a real time basis, VE (direct effect) and the VI of vaccination programmes (indirect and overall effect) against laboratory confirmed cases of influenza (types/subtypes) and pneumococcal disease (serotypes), and clinical outcomes. Cost effectiveness analysis will be conducted. Results will allow to understand factors affecting specific VE, the duration of protection of influenza and pneumococcal vaccines, the interaction between vaccines, the role of repeated vaccinations, the occurrence of serotype replacement (pneumococcus); identify vaccine types and brands with low VE; guide the decision of the WHO committees on vaccine strain selection (influenza); provide robust benefit indicators (VE and VI) and cost benefit and effectiveness results; guide vaccination strategies (schedules, doses, boosters). This EU member state collaboration will respond to questions that require studies based on large sample sizes and sharing of expertise that cannot be achieved by one country alone. It will allow the best methods to be used and results to benefit to all EU countries whatever their current public health achievements. Results will be shared with international partners.
Agency: Cordis | Branch: FP7 | Program: CP-CSA-Infra-PP | Phase: INFRA-2010-2.2.8 | Award Amount: 4.79M | Year: 2010
In the context of the emerging and re-emerging infectious diseases involving highly pathogenic microorganisms, European countries have to be well-prepared to face such threats. However, the Biosafety Level 4 (BSL4) capacity in Europe is not sufficient enough to cover the efficient development of diagnosis, prophylactic and therapeutics means against these pathogens. Moreover, there is no global coordination of activities and harmonization of practice in this field. Therefore, the ERINHA project proposes the creation of a top world-class BSL4 research infrastructure that will address the actual European capacity sparseness. The project plans to conduct five main actions which are: (i) Building additional BSL4 areas in several existing BSL4 laboratories, (ii) Building BSL4 laboratories in strategically selected EU countries that are lacking one, (iii) Building a support infrastructure around BSL4 laboratories mainly dedicated to host scientific visitors and staff, (iv) Setting-up the user access to the ERINHA infrastructure, (v) Establishing coordination capacities for efficient dispatching and control of all activities. For 46 months, the ERINHA Preparatory Phase will focus on (i) Identifying relevant sites in Europe for new BSL4 constructions or major upgrades, (ii) Getting political and financial commitments from National, European or International concerned entities to support construction, (iii) Establishing a secured and validated financial plan for construction, (iv) Defining and implementing an appropriate governance and legal framework, (v) Harmonising and disseminating common procedures related to L4 biological resources, biosafety and biosecurity management, (iv) Defining and implementing joint training programs to operate in BSL4 facilities, (vii) Identifying the ERINHAs users and establishing rules for access. These achievements will allow the ERINHA project to reach the legal, financial and technical maturity to proceed to the construction phase.
Agency: Cordis | Branch: FP7 | Program: CSA-CA | Phase: KBBE.2010.4-01 | Award Amount: 1.12M | Year: 2011
The objective is to further integrate/refine the EuroFIR Food Platform (EFP), to improve/support the ways research is undertaken into relationships between food, diets and health in Europe. Our focus is on extending application and exploitation of validated food data and tools for pan-European nutrition studies and networked usage, implementation of standards and best practice. This together forms the basis of long-term sustainability through the newly established legal entity EuroFIR AISBL). Six Work Packages are included: Quality standards & certification; Systems integration & operational support; Integration & business development; Training; Dissemination & Management. The revised consortium has 35 existing EuroFIR partners (18 as 3rd parties/EuroFIR AISBL members). The already achieved high-level institutional commitment will be further strengthened. The new General Assembly consists of executive representatives of all beneficiaries (who are also AISBL Members), thus real and durable integration is achievable. The Executive Board will work closely with EuroFIR AISBL to provide an integrated approach to joint activities and stakeholder engagements. A high-level External Advisory Board of key users/stakeholders from Europe and internationally will ensure that food data, other products and services are fine-tuned to stakeholders needs, keeping Europe at the forefront of leadership and innovation in this area. Outputs are consistent with the ETP `Food for Life and will further support Theme 2 (FP7) in food and nutrition research contributing to the structuring of the European Research Area and world-class scientific/technological excellence. Additionally, the outputs bring the EFP in alignment with the current European CEN Standard on Food Data and its application.
Agency: Cordis | Branch: H2020 | Program: CSA | Phase: INFRADEV-2-2015 | Award Amount: 1.51M | Year: 2016
ERINHA2 aims to complete the work carried out during the first preparatory phase (PP1) - ERINHA - in order to reach the financial, administrative and technical maturity necessary to complete the establishment of the Research Infrastructre and ensure that the operation phase can begin in 2018. ERINHA2 will therefore finalise the decision to use the status of an association and prepare the necessary legal document to register the RI depending on the country voted on to host the Central Coordinating Unit. ERINHA2 will prepare all procedures and protocols (human resources, IPR, ethics) needed to effectively operate the RI. The financial and business plans prepared in ERINHA (PP1) will updated and presented to national and international stakeholders to obtain their agreement to fund the infrastructure. An overarching group of activities - WP5, Stakeholders and commitment - will aim to accompany all partner countries in their efforts to obtain agreements and funding. This WP5 will ensure all relevant stakeholders and potential users are informed of the progress, services and benefits of ERINHA. The utlimate outcome of ERINHA2 will be the signtature of the ERINHA statutes among the founding countries to officially establish the RI and enter into the construction phase.